Traws Pharma Changes Fiscal Year End
Ticker: TRAW · Form: 8-K · Filed: Jun 28, 2024 · CIK: 1130598
| Field | Detail |
|---|---|
| Company | Traws Pharma, Inc. (TRAW) |
| Form Type | 8-K |
| Filed Date | Jun 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, fiscal-year-change
TL;DR
Traws Pharma (formerly Onconova) is shifting its fiscal year end to Dec 31, effective June 26, 2024.
AI Summary
Traws Pharma, Inc. filed an 8-K on June 28, 2024, reporting a change in its fiscal year end to December 31st, effective as of June 26, 2024. The company, previously known as Onconova Therapeutics, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.
Why It Matters
This change in fiscal year end may impact reporting schedules and financial analysis timelines for investors and stakeholders.
Risk Assessment
Risk Level: low — The filing solely concerns an administrative change in the company's fiscal year end, with no immediate financial or operational implications disclosed.
Key Players & Entities
- Traws Pharma, Inc. (company) — Registrant
- Onconova Therapeutics, Inc. (company) — Former company name
- June 26, 2024 (date) — Effective date of fiscal year change
- June 28, 2024 (date) — Filing date
- December 31 (date) — New fiscal year end
FAQ
What is the new fiscal year end for Traws Pharma, Inc.?
The new fiscal year end for Traws Pharma, Inc. is December 31.
When did the change in fiscal year end become effective?
The change in fiscal year end became effective as of June 26, 2024.
What was Traws Pharma, Inc. formerly known as?
Traws Pharma, Inc. was formerly known as Onconova Therapeutics, Inc.
In which state is Traws Pharma, Inc. incorporated?
Traws Pharma, Inc. is incorporated in Delaware.
What is the filing date of this 8-K report?
This 8-K report was filed on June 28, 2024.
Filing Stats: 475 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-06-28 17:00:38
Key Financial Figures
- $0.01 — f the Company's common stock, par value $0.01 per share ("Common Stock") to one-third
Filing Documents
- tm2418453d1_8k.htm (8-K) — 24KB
- tm2418453d1_ex3-1.htm (EX-3.1) — 9KB
- 0001104659-24-076343.txt ( ) — 204KB
- tmb-20240626.xsd (EX-101.SCH) — 3KB
- tmb-20240626_lab.xml (EX-101.LAB) — 33KB
- tmb-20240626_pre.xml (EX-101.PRE) — 22KB
- tm2418453d1_8k_htm.xml (XML) — 4KB
03
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On June 26, 2024, the Board adopted an amendment to the Company's Amended and Restated Bylaws (the "Bylaws Amendment"), solely to reduce the quorum requirement for all meetings of stockholders of the Company from a majority of the issued and outstanding shares of the Company's common stock, par value $0.01 per share ("Common Stock") to one-third of the issued and outstanding shares of Common Stock. The foregoing description of the Bylaws Amendment is a summary and is qualified in its entirety by reference to the full text of the Bylaws Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 3.1 Amendment to Amended and Restated Bylaws of Traws Pharma, Inc., effective as of June 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRAWS PHARMA, Inc. Date: June 28, 2024 By: /s/ MARK GUERIN Mark Guerin Chief Financial Officer